Old Web
English
Sign In
Acemap
>
Paper
>
Correction to: Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study.
Correction to: Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study.
2021
Jai Perumal
Roumen Balabanov
Ray Su
Roger Chang
Laura J. Balcer
Steven L. Galetta
Denise Campagnolo
Robin Avila
Lily Lee
Danette Rutledge
Robert J. Fox
Keywords:
MEDLINE
relapsing remitting
Internal medicine
Medicine
Natalizumab
Rheumatology
Multiple sclerosis
pharmacology toxicology
open label study
Correction
Source
Cite
Save
Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI
[]